Table 1.
Characteristics of the study population
| Placebo group | Nutraceutical group | Total | p-value | ||||
|---|---|---|---|---|---|---|---|
| N (%) | Mean (SD) | N (%) | Mean (SD) | N (%) | Mean (SD) | ||
| Sex | |||||||
| Male | 28 (53.8) | 30 (56.6) | 58 (55.2) | 0.85 | |||
| Female | 24 (46.2) | 23 (43.4) | 47 (44.8) | ||||
| Total | 52 (100) | 53 (100) | 105 (100) | ||||
| Age | 51.5 (13.2) | 51.7 (13.0) | 51.6 (13.1) | 0.95 | |||
| Previous obstructive uropathy | 19 (36.5) | 21 (39.6) | 40 (38.1) | 0.84 | |||
| Previous stenting | 19 (36.5) | 22 (41.5) | 41 (39) | 0.69 | |||
| Urolithiasis as cause of current implantation | 41 (78.8) | 41 (77.4) | 82 (78.1) | 0.85 | |||
| Type of calculi | |||||||
| Calcium oxalate | 19 (46.3) | 21 (51.2) | 40 (48.8) | 0.80 | |||
| Others | 22 (53.7) | 20 (48.7) | 42 (51.2) | ||||
| Total | 41 (100) | 41 (100) | 82 (100) | ||||
| Stent material | |||||||
| Polyurethane | 23 (44.3) | 20 (37.7) | 43 (40.9) | 0.45 | |||
| Silicone | 1 (1.9) | 0 (0) | 1 (1) | ||||
| Percuflex | 28 (53.8) | 33 (62.3) | 61 (58.1) | ||||
| Implantation period (days) | 39.7 (14.9) | 35.4 (12.7) | 37.54 (13.9) | 0.12 | |||
| Basal urinary pH | 43 (100) | 6.2 (0.6) | 44 (100) | 6.3 (0.8) | 87 (100) | 6.3 (0.7) | 0.62 |
SD standard deviation
Group homogeneity at baseline